Fairmount's lock-up prevents any selling by the activist for 60 days post-offering (through early December 2026). Monitor for any amendment after the lock-up expires that could signal a change in strategy or stake reduction.
Price Chart
Executive Summary
Fairmount Funds Management LLC filed Amendment No. 8 to its Schedule 13D on Spyre Therapeutics, reporting no change in beneficial ownership since the prior amendment. The filing is solely to disclose that Fairmount entered into a 60-day lock-up agreement with underwriters in connection with Spyre's October 7, 2026 underwritten public offering, in which Fairmount did not participate. Fairmount's aggregate beneficial ownership remains at 9.19% (9,354,200 shares on an as-converted basis, subject to a 9.99% blocker).
Key Financial Metrics
Key Facts
- Fairmount Funds Management LLC filed Amendment No. 8 to Schedule 13D on Spyre Therapeutics, dated October 9, 2026.
- Beneficial ownership unchanged from Amendment No. 7 (June 23, 2026): 9.19% of common stock on an as-converted basis.
- Fairmount entered into a 60-day lock-up agreement with Jefferies, TD Securities, Leerink Partners, and Stifel in connection with Spyre's October 7, 2026 underwritten public offering.
- Fairmount did not purchase any securities or participate in the offering.
- The lock-up restricts sales of Spyre securities for 60 days following the final prospectus supplement date, subject to underwriter consent.
- Fairmount's stake consists of 812,076 common shares, 9,100,160 shares issuable upon conversion of Series A Preferred (subject to 9.99% blocker), and 228,646 option shares.
Financial Impact
No financial impact from this filing; Fairmount's stake unchanged and no participation in the offering. The lock-up is a standard underwriting condition.
Risk Factors
- Lock-up expiration in ~60 days could precede a stake reduction or sale by Fairmount.
- No change in stated purpose or demands — Fairmount's intentions remain opaque beyond the lock-up disclosure.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001104659-26-115087 |
| Document: 0001104659-26-115087-index.html | 0001104659-26-115087 |
| Document: 0001104659-26-115087.txt | 0001104659-26-115087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 9, 2026 18d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 7, 2026 20d ago | 8-K | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 6, 2026 21d ago | 424B5 | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | 424B5 | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 2, 2026 25d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $99.04 (−6.82%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $99.04 (−11.31%) |
Aug 10, 2026 11w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $99.04 (+3.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers